Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27551142 | 0.86 | L3MBTL1 (0.54) | KMT2AMEN1L3MBTL1PTPRCLMNA | |
| SCHEMBL27570822 | 0.86 | L3MBTL1 (0.54) | KMT2AMEN1L3MBTL1PTPRCLMNA | |
| SCHEMBL19193984 | 0.86 | L3MBTL1 (0.54) | KMT2AMEN1L3MBTL1PTPRCLMNA | |
| SCHEMBL5246965 | 0.84 | CTSS (0.48) | KMT2AMEN1L3MBTL1PTPRCCTSS | |
| SCHEMBL6359621 | 0.83 | RIPK1 (0.50) | L3MBTL1PTPRCCTSSCTSK | |
| SCHEMBL6359617 | 0.83 | RIPK1 (0.50) | L3MBTL1PTPRCCTSSCTSK | |
| SCHEMBL4679533 | 0.83 | KMT2A (0.55) | TDP1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL16680856 | 0.82 | ALDH1A1 (0.44) | L3MBTL1PTPRCALDH1A1CTSSCTSK | |
| SCHEMBL3768794 | 0.82 | L3MBTL1 (0.43) | TDP1KMT2AL3MBTL1PTPRCCTSS | |
| SCHEMBL4167953 | 0.82 | ALDH1A1 (0.44) | L3MBTL1PTPRCALDH1A1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005531-A | Synthesis method of chiral unnatural amino acid derivative | 内蒙古大学 | 2024-05-10 | — | — | CN | claimed |
| CN-108299482-A | F-BPA and its intermediate synthetic method, intermediate and its application | 中国原子能科学研究院 | 2018-07-20 | — | — | CN | claimed |
| CN-119330846-A | Resolution method and intermediate of phenylalanine derivatives | 中硼（厦门）生物医药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-116348109-B | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-118307428-B | Chiral alpha unnatural amino acid and preparation method thereof by rare noble metal complex | 北京元延医药科技股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119119229-A | Unnatural amino acids and their use as probes | 北京大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-119100949-A | Unnatural amino acids and their use in the construction of fluorescent proteins and probes | 北京大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-118561839-A | Synthesis method of N- (8-oxo-7, 8-dihydropyrido [3,4-c ] pyridazin-3-yl) cyclopropane formamide | 西安石油大学 | 2024-08-30 | — | — | CN | disclosed |
| CN-117924173-B | Aniline quaternary ammonium salt chiral phase transfer catalyst and application thereof in asymmetric alkylation catalysis of amino acid derivatives | 广东工业大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307428-A | Chiral alpha unnatural amino acid and preparation method thereof by rare noble metal complex | 北京元延医药科技股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118005531-A | Synthesis method of chiral unnatural amino acid derivative | 内蒙古大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-108299482-A | F-BPA and its intermediate synthetic method, intermediate and its application | 中国原子能科学研究院 | 2018-07-20 | — | — | CN | disclosed |
| CN-105968085-A | Preparation method of L-tetra-substituted styrene-acrylate ammonia-alcohol compound | 四川大学 | 2016-09-28 | — | — | CN | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | TDP1 1448/4885KMT2A 1078/4885MEN1 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.